Elicio Therapeutics Inc. - Asset Resilience Ratio

Latest as of March 2022: 22.84%

Elicio Therapeutics Inc. (ELTX) has an Asset Resilience Ratio of 22.84% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$18.56 Million
Cash + Short-term Investments

Total Assets

$81.26 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Elicio Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Check strategic asset allocation of Elicio Therapeutics Inc. to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Elicio Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ELTX market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $18.56 Million 22.84%
Total Liquid Assets $18.56 Million 22.84%

Asset Resilience Insights

  • Good Liquidity Position: Elicio Therapeutics Inc. maintains a healthy 22.84% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Elicio Therapeutics Inc. Industry Peers by Asset Resilience Ratio

Compare Elicio Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Prostemics Co. Ltd
KQ:203690
Biotechnology 0.31%
ORUM
KQ:475830
Biotechnology 82.74%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
TG Therapeutics Inc
NASDAQ:TGTX
Biotechnology 4.72%
Green Cross Holdings Preference Shares
KO:005257
Biotechnology 0.50%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 33.70%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Cybin Inc
NEO:CYBN
Biotechnology 0.21%

Annual Asset Resilience Ratio for Elicio Therapeutics Inc. (None–None)

The table below shows the annual Asset Resilience Ratio data for Elicio Therapeutics Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points

About Elicio Therapeutics Inc.

NASDAQ:ELTX USA Biotechnology
Market Cap
$59.93 Million
Market Cap Rank
#21663 Global
#4782 in USA
Share Price
$3.14
Change (1 day)
-1.57%
52-Week Range
$2.76 - $14.85
All Time High
$257.40
About

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more